More on CTMX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.75 |
|
|||
| Open | $2.74 | ||||
| 52 Wk High | $24.68 | ||||
| 52 Wk Low | $9.10 | ||||
| Day High | $2.78 | ||||
| Day Low | $2.66 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,031,504 | ||||
- Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
- FDA grants fast track status to CytomX drug for colorectal cancer
- CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Point72 Asset Management, L.P.
- Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Kynam Capital Management, LP
- CytomX Therapeutics (CTMX) PT Lowered to $11 at JPMorgan
- CytomX Therapeutics (CTMX) PT Lowered to $14 at Guggenheim
- Form SCHEDULE 13G CytomX Therapeutics, Filed by: STATE STREET CORP
- Form S-8 CytomX Therapeutics,
- CytomX Therapeutics (CTMX) Misses Q2 EPS by 1c
Entities mentioned with CTMX
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
